JP2022518210A5 - - Google Patents
Info
- Publication number
- JP2022518210A5 JP2022518210A5 JP2021540822A JP2021540822A JP2022518210A5 JP 2022518210 A5 JP2022518210 A5 JP 2022518210A5 JP 2021540822 A JP2021540822 A JP 2021540822A JP 2021540822 A JP2021540822 A JP 2021540822A JP 2022518210 A5 JP2022518210 A5 JP 2022518210A5
- Authority
- JP
- Japan
- Prior art keywords
- referred
- sequence
- sar
- seq
- peptide ligand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1900527.1A GB201900527D0 (en) | 2019-01-15 | 2019-01-15 | Bicyclic peptide ligands specific for integrin avb3 |
| GB1900527.1 | 2019-01-15 | ||
| PCT/GB2020/050071 WO2020148527A1 (en) | 2019-01-15 | 2020-01-15 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR INTEGRIN αVβ3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022518210A JP2022518210A (ja) | 2022-03-14 |
| JP2022518210A5 true JP2022518210A5 (enExample) | 2023-01-25 |
Family
ID=65528151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540822A Pending JP2022518210A (ja) | 2019-01-15 | 2020-01-15 | インテグリンαｖβ３に特異的な二環式ペプチドリガンド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220064221A1 (enExample) |
| EP (1) | EP3966233A1 (enExample) |
| JP (1) | JP2022518210A (enExample) |
| CN (1) | CN113439088A (enExample) |
| GB (1) | GB201900527D0 (enExample) |
| WO (1) | WO2020148527A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| GB201900529D0 (en) | 2019-01-15 | 2019-03-06 | Bicycletx Ltd | Bicyclic peptide ligands specific for CD38 |
| GB201900528D0 (en) * | 2019-01-15 | 2019-03-06 | Bicyclerd Ltd | Bicyclic peptide ligands specific for integrin AVB3 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2653545A1 (en) | 2008-02-05 | 2013-10-23 | Bicycle Therapeutics Limited | Methods and compositions |
| US9073974B2 (en) * | 2009-12-21 | 2015-07-07 | The Regents Of The University Of California | RGD-containing cyclic peptides |
| US20140274759A1 (en) * | 2013-03-15 | 2014-09-18 | Bicycle Therapeutics Limited | Modification of polypeptides |
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| EP3645549A1 (en) * | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| GB201810329D0 (en) * | 2018-06-22 | 2018-08-08 | Bicycletx Ltd | Peptide ligands for binding to integrin avB3 |
-
2019
- 2019-01-15 GB GBGB1900527.1A patent/GB201900527D0/en not_active Ceased
-
2020
- 2020-01-15 EP EP20701120.6A patent/EP3966233A1/en not_active Withdrawn
- 2020-01-15 JP JP2021540822A patent/JP2022518210A/ja active Pending
- 2020-01-15 US US17/422,935 patent/US20220064221A1/en not_active Abandoned
- 2020-01-15 CN CN202080014773.9A patent/CN113439088A/zh active Pending
- 2020-01-15 WO PCT/GB2020/050071 patent/WO2020148527A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518210A5 (enExample) | ||
| JP2022517698A5 (enExample) | ||
| JP2022518695A5 (enExample) | ||
| JP2022517040A5 (enExample) | ||
| JP2022517442A5 (enExample) | ||
| JP2022512478A5 (enExample) | ||
| JP2022514687A5 (enExample) | ||
| JP2022514255A5 (enExample) | ||
| JP2022513223A5 (enExample) | ||
| JP2022532134A5 (enExample) | ||
| JP2022552839A5 (enExample) | ||
| JP2022517399A5 (enExample) | ||
| JP2022544058A5 (enExample) | ||
| JP5537431B2 (ja) | ウイルス融合のインヒビターのコレステロール誘導体 | |
| JP2022513806A5 (enExample) | ||
| WO2017066484A2 (en) | Nsp10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications | |
| JP2008525491A5 (enExample) | ||
| CN105829336A (zh) | α-螺旋细胞穿透肽多聚体、其产生方法及其用途 | |
| JP2004514644A5 (enExample) | ||
| CA2931694C (en) | Fatty acid derivatives of dimeric peptide ligands of psd-95 and use thereof for treating excitotoxic disease | |
| JP2023537951A5 (enExample) | ||
| JPWO2000059932A1 (ja) | インフルエンザウイルス・ヘマグルチニン結合性ペプチド | |
| US8906355B2 (en) | Synthetic stereoisomer peptides in the retro-inverso and inverso configuration, and with cyclic and linear structure, their polymer conjugates, their encapsulation in polymer particles, and uses thereof | |
| JP2022515720A5 (enExample) | ||
| Redman et al. | Pharmacokinetic and chemical synthesis optimization of a potent D-peptide HIV entry inhibitor suitable for extended-release delivery |